{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:04:45Z","timestamp":1786377885555,"version":"build-2736575974"},"reference-count":68,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0147319","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T18:41:20Z","timestamp":1453833680000},"page":"e0147319","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["An Alzheimer\u2019s Disease-Derived Biomarker Signature Identifies Parkinson\u2019s Disease Patients with Dementia"],"prefix":"10.1371","volume":"11","author":[{"given":"Yosef","family":"Berlyand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon X.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Mellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimit","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Rick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Davatzikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Hurtig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Q.","family":"Trojanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice S.","family":"Chen-Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,1,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cell.2005.02.008","article-title":"Twenty years of the Alzheimer\u2019s disease amyloid hypothesis: a genetic perspective","volume":"120","author":"RE Tanzi","year":"2005","journal-title":"Cell"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000275491","article-title":"Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries","volume":"34","author":"A Wright Willis","year":"2010","journal-title":"Neuroepidemiology"},{"issue":"Pt 5","key":"ref3","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson's disease: substantia nigra regional selectivity","volume":"114","author":"JM Fearnley","year":"1991","journal-title":"Brain"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/brain\/awm111","article-title":"Evolution of cognitive dysfunction in an incident Parkinson's disease cohort","volume":"130","author":"CH Williams-Gray","year":"2007","journal-title":"Brain"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. 2008;23: 837\u2013844.","DOI":"10.1002\/mds.21956"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1212\/01.wnl.0000306632.43729.24","article-title":"Dementia and survival in Parkinson disease: a 12-year population study","volume":"70","author":"TC Buter","year":"2008","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/archneur.1992.00530290076015","article-title":"A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender","volume":"49","author":"R Mayeux","year":"1992","journal-title":"Arch Neurol"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Rosenthal E, Brennan L, Xie S, Hurtig H, Milber J, Weintraub D, et al. Association between cognition and function in patients with Parkinson disease with and without dementia. 2010;25: 1170\u20131176.","DOI":"10.1002\/mds.23073"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/WNL.60.1.87","article-title":"The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism","volume":"60","author":"JC Pressley","year":"2003","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The parkinson progression marker initiative (PPMI)","volume":"95","author":"K Marek","year":"2011","journal-title":"Prog Neurobiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1002\/ana.21602","article-title":"Biomarkers for Parkison's disease: tools to assess Parkinson's disease onset and progression","volume":"64","author":"K Marek","year":"2008","journal-title":"Ann Neurol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"79ps14","DOI":"10.1126\/scitranslmed.3002488","article-title":"Biomarkers for Parkinson's disease","volume":"3","author":"TB Sherer","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, et al. Cerebrospinal fluid Tau\/\u03b1\u2010synuclein ratio in Parkinson's disease and degenerative dementias. 2011;26: 1428\u20131435.","DOI":"10.1002\/mds.23670"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","article-title":"What are biomarkers?","volume":"5","author":"K Strimbu","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/archneur.1995.00540310069018","article-title":"The frequency and associated risk factors for dementia in patients with Parkinson's disease","volume":"52","author":"K Marder","year":"1995","journal-title":"Arch Neurol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1212\/WNL.0b013e3181bf992f","article-title":"Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort","volume":"73","author":"EY Uc","year":"2009","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1212\/WNL.54.8.1596","article-title":"A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease","volume":"54","author":"TA Hughes","year":"2000","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/WNL.56.6.730","article-title":"Risk of dementia in Parkinson's disease: a community-based, prospective study","volume":"56","author":"D Aarsland","year":"2001","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, et al. Genetic influences on cognitive decline in Parkinson's disease. 2012;27: 512\u2013518.","DOI":"10.1002\/mds.24946"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1093\/brain\/awp245","article-title":"The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort","volume":"132","author":"CH Williams-Gray","year":"2009","journal-title":"Brain"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease","volume":"132","author":"J Neumann","year":"2009","journal-title":"Brain"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid {beta} 1\u201342 predicts cognitive decline in Parkinson disease","volume":"75","author":"A Siderowf","year":"2010","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"LM Shaw","year":"2009","journal-title":"Ann Neurol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00415-012-6648-6","article-title":"Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson\u2019s disease patients","volume":"260","author":"MT Pellecchia","year":"2013","journal-title":"J Neurol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ana.22271","article-title":"Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease","volume":"69","author":"AS Chen\u2010Plotkin","year":"2011","journal-title":"Ann Neurol"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Mollenhauer B, Rochester L, Chen\u2010Plotkin A, Brooks D. What can biomarkers tell us about cognition in Parkinson's disease?. 2014;29: 622\u2013633.","DOI":"10.1002\/mds.25846"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1093\/brain\/awp091","article-title":"Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index","volume":"132","author":"C Davatzikos","year":"2009","journal-title":"Brain"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/brain\/awr277","article-title":"Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease","volume":"135","author":"D Weintraub","year":"2012","journal-title":"Brain"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.neuron.2014.10.031","article-title":"Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases","volume":"84","author":"AS Chen-Plotkin","year":"2014","journal-title":"Neuron"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s004019900168","article-title":"Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson\u2019s disease","volume":"100","author":"P Mattila","year":"2000","journal-title":"Acta Neuropathol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/archneur.1993.00540020018011","article-title":"A clinicopathologic study of 100 cases of Parkinson's disease","volume":"50","author":"AJ Hughes","year":"1993","journal-title":"Arch Neurol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WAD.0b013e31819c5ef4","article-title":"Parkinson disease with dementia: comparing patients with and without Alzheimer pathology","volume":"23","author":"MN Sabbagh","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"DJ Irwin","year":"2012","journal-title":"Ann Neurol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00401-008-0347-5","article-title":"Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease","volume":"115","author":"KA Jellinger","year":"2008","journal-title":"Acta Neuropathol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease","volume":"51","author":"WR Gibb","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2014.11.001","article-title":"2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception","volume":"11","author":"MW Weiner","year":"2015","journal-title":"Alzheimers Dement"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Mollenhauer B, Rochester L, Chen\u2010Plotkin A, Brooks D. What can biomarkers tell us about cognition in Parkinson's disease?. 2014;29: 622\u2013633.","DOI":"10.1002\/mds.25846"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Lucas JA, Ivnik RJ, Smith GE, Bohac DL, Tangalos EG, Kokmen E, et al. Normative data for the Mattis dementia rating scale. 1998;20: 536\u2013547.","DOI":"10.1076\/jcen.20.4.536.1469"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Weintraub D, Oehlberg KA, Katz IR, Stern MB. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. 2006;14: 169\u2013175.","DOI":"10.1097\/01.JGP.0000192488.66049.4b"},{"key":"ref40","unstructured":"Fahn S, Elton R. Unified rating scale for Parkinson\u2019s disease. 1987: 153\u2013163."},{"key":"ref41","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1076\/clin.13.3.348.1749","article-title":"Construct and concurrent validity of the Hopkins Verbal Learning Test-revised","volume":"13","author":"AM Shapiro","year":"1999","journal-title":"Clin Neuropsychol"},{"key":"ref42","article-title":"The Hopkins Verbal Learning Test-Revised","author":"J BR Brandt","year":"2001","journal-title":"Psychological Assessment Resources"},{"key":"ref43","first-page":"195","article-title":"Evidence for impaired encoding and retrieval memory profiles in Parkinson disease","volume":"17","author":"D Weintraub","year":"2004","journal-title":"Cogn Behav Neurol"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Chahine LM, Qiang J, Ashbridge E, Minger J, Yearout D, Horn S, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. 2013;70: 852\u2013858.","DOI":"10.1001\/jamaneurol.2013.1274"},{"key":"ref45","unstructured":"Hoehn M. Yahr. 1967: V7."},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","article-title":"Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group","volume":"40","author":"J Jankovic","year":"1990","journal-title":"Neurology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/WNL.0b013e3182735e9a","article-title":"GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology","volume":"79","author":"D Tsuang","year":"2012","journal-title":"Neurology"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1373\/clinchem.2004.039347","article-title":"Simultaneous measurement of beta-amyloid(1\u201342), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology","volume":"51","author":"A Olsson","year":"2005","journal-title":"Clin Chem"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Su Y, Yajima M, Gelman AE, Hill J. Multiple imputation with diagnostics (mi) in R: Opening windows into the black box. 2011;45: 1\u201331.","DOI":"10.18637\/jss.v045.i02"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of [alpha]-synuclein, tau and amyloid-[beta] pathologies. 2013;14: 626\u2013636.","DOI":"10.1038\/nrn3549"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000094871","article-title":"Beta-amlyoid 1\u201342 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia","volume":"22","author":"B Mollenhauer","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"H Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"ref53","first-page":"89","article-title":"Anonymous Parkinson\u2019s Disease and Related Disorders","author":"H Braak","year":"2006"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/NEN.0b013e31816362aa","article-title":"Striatal beta-amyloid deposition in Parkinson disease with dementia","volume":"67","author":"ME Kalaitzakis","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/brain\/awr031","article-title":"Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?","volume":"134","author":"Y Compta","year":"2011","journal-title":"Brain"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-008-0406-y","article-title":"A critical reappraisal of current staging of Lewy-related pathology in human brain","volume":"116","author":"KA Jellinger","year":"2008","journal-title":"Acta Neuropathol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s007020200027","article-title":"Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease","volume":"109","author":"K Jellinger","year":"2002","journal-title":"J Neural Transm"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1037\/h0091766","article-title":"Differentiation of Alzheimer's, Huntington's, and Parkinson's disease patients on the basis of verbal learning characteristics","volume":"3","author":"JH Kramer","year":"1989","journal-title":"Neuropsychology"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archneur.1993.00540040036010","article-title":"Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases","volume":"50","author":"B Pillon","year":"1993","journal-title":"Arch Neurol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline","volume":"30","author":"LK Clinton","year":"2010","journal-title":"J Neurosci"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00401-002-0563-3","article-title":"Concurrence of \u03b1-synuclein and tau brain pathology in the Contursi kindred","volume":"104","author":"JE Duda","year":"2002","journal-title":"Acta Neuropathol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.tins.2004.01.007","article-title":"More than just two peas in a pod: common amyloidogenic properties of tau and \u03b1-synuclein in neurodegenerative diseases","volume":"27","author":"VM Lee","year":"2004","journal-title":"Trends Neurosci"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1126\/science.1082324","article-title":"Initiation and synergistic fibrillization of tau and alpha-synuclein","volume":"300","author":"BI Giasson","year":"2003","journal-title":"Science"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"RS Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"S Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"ref66","unstructured":"AstraZeneca. An Efficacy and Safety Study of AZD3293 in Early Alzheimer's Disease (AMARANTH)."},{"key":"ref67","unstructured":"Eli Lilly and Company. Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)."},{"key":"ref68","unstructured":"Eisai Inc. Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild Dementia Due to Alzheimer's Disease."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0147319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T11:38:16Z","timestamp":1600083496000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0147319"}},"subtitle":[],"editor":[{"given":"Pradeep","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,1,26]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0147319","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,26]]}}}